

Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	14.4	97.5	(53.3-163.6)	Male	12	9.9	121.0	(62.5-211.4)
Female	7	5.9	119.1	(47.7-245.4)	Female	8	8.8	91.0	(39.2-179.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.0	nc	(nc-nc)	Male	7	3.2	220.2	(88.2-453.8)
Female	1	3.0	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	4	8.7	nc	(nc-nc)
Female	59	72.4	81.5	(62.0-105.1)	Female	6	8.4	71.6	(26.2-155.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	7	7.8	89.2	(35.7-183.7)
<u>Colon / Rectum</u>					Female	8	3.9	206.9	(89.1-407.6)
Male	22	15.9	138.1	(86.5-209.1)	<u>Ovary</u>				
Female	20	16.7	120.0	(73.3-185.4)	Female	5	6.2	80.8	(26.1-188.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.0	151.7	(55.4-330.2)	Male	7	5.6	125.3	(50.2-258.2)
Female	0	1.2	nc	(nc-nc)	Female	3	6.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	42	48.8	86.1	(62.1-116.4)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.5	nc	(nc-nc)
Male	17	9.4	181.2	(105.5-290.1)	Female	4	2.4	nc	(nc-nc)
Female	7	5.7	123.4	(49.4-254.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	6	0.8	741.1	(270.6-1613.1)	Male	3	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	16	13.9	115.4	(65.9-187.4)
Male	5	6.0	83.2	(26.8-194.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.9	121.7	(44.4-264.8)	Female	18	17.2	104.7	(62.0-165.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.7	105.4	(38.5-229.4)	Male	216	198.1	109.0	(95.0-124.6)
Female	2	2.1	nc	(nc-nc)	Female	245	235.5	104.0	(91.4-117.9)
<u>Lung and Bronchus</u>									
Male	35	26.5	132.3	(92.2-184.0)					
Female	41	32.0	128.3	(92.0-174.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	21.6	87.9	(52.9-137.3)	Male	17	15.1	112.3	(65.4-179.8)
Female	4	7.9	nc	(nc-nc)	Female	16	12.4	128.9	(73.6-209.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.7	128.4	(46.9-279.5)	Male	3	4.8	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	16	13.4	119.8	(68.5-194.6)
Female	118	103.5	114.1	(94.4-136.6)	Female	8	11.6	69.2	(29.8-136.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.6	nc	(nc-nc)	Male	10	12.2	81.8	(39.2-150.5)
<u>Colon / Rectum</u>					Female	5	5.3	94.9	(30.6-221.5)
Male	24	25.1	95.5	(61.2-142.1)	<u>Ovary</u>				
Female	20	24.2	82.8	(50.5-127.8)	Female	8	8.6	93.0	(40.0-183.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	6.0	100.8	(36.8-219.4)	Male	7	8.5	82.6	(33.1-170.2)
Female	3	1.6	nc	(nc-nc)	Female	8	8.2	97.2	(41.9-191.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.8	nc	(nc-nc)	Male	79	72.3	109.3	(86.5-136.2)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.4	nc	(nc-nc)
Male	7	14.5	48.4	(19.4-99.8)	Female	1	3.3	nc	(nc-nc)
Female	10	7.8	127.9	(61.2-235.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.5	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	7	7.0	100.7	(40.3-207.4)
<u>Leukemia</u>					Female	20	20.3	98.5	(60.1-152.1)
Male	8	9.2	86.7	(37.4-170.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	6.7	134.3	(61.3-255.0)	Female	14	22.7	61.6	(33.7-103.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	8.7	68.7	(25.1-149.6)	Male	257	299.7	85.7	(75.6-96.9)
Female	2	2.7	nc	(nc-nc)	Female	307	327.4	93.8	(83.6-104.9)
<u>Lung and Bronchus</u>									
Male	18	38.9	46.3	(27.4-73.1)					
Female	27	42.2	64.0	(42.2-93.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	13.4	148.8	(90.9-229.9)	Male	4	8.5	nc	(nc-nc)
Female	4	4.3	nc	(nc-nc)	Female	5	5.8	86.3	(27.8-201.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.4	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	9	7.4	121.0	(55.2-229.7)
Female	50	47.8	104.6	(77.6-137.9)	Female	13	5.9	221.2	(117.7-378.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	3	6.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.6	nc	(nc-nc)
Male	18	13.7	131.5	(77.9-207.9)	<u>Ovary</u>				
Female	13	12.0	108.0	(57.4-184.7)	Female	5	4.1	123.3	(39.7-287.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.2	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	7	4.5	155.3	(62.2-319.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	44	36.5	120.6	(87.6-162.0)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.1	nc	(nc-nc)
Male	5	7.3	68.4	(22.1-159.7)	Female	0	1.7	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.7	nc	(nc-nc)
Male	3	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	8	8.3	96.0	(41.3-189.1)
Male	3	5.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	3.3	240.9	(103.7-474.7)	Female	6	11.0	54.5	(19.9-118.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.5	nc	(nc-nc)	Male	178	163.8	108.7	(93.3-125.9)
Female	1	1.4	nc	(nc-nc)	Female	165	159.9	103.2	(88.0-120.2)
<u>Lung and Bronchus</u>									
Male	30	22.8	131.3	(88.6-187.5)					
Female	22	23.2	95.0	(59.5-143.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.9	70.8	(28.4-145.9)	Male	5	6.1	81.6	(26.3-190.5)
Female	3	3.8	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.4	110.7	(40.4-240.9)
Female	35	41.8	83.8	(58.4-116.6)	Female	7	5.1	136.2	(54.6-280.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	5	4.5	112.0	(36.1-261.4)
<u>Colon / Rectum</u>					Female	0	2.3	nc	(nc-nc)
Male	13	10.0	129.8	(69.1-222.0)	<u>Ovary</u>				
Female	8	10.7	75.0	(32.3-147.7)	Female	1	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.4	nc	(nc-nc)	Male	6	3.6	167.0	(61.0-363.6)
Female	0	0.7	nc	(nc-nc)	Female	7	3.9	178.9	(71.7-368.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	22	29.6	74.3	(46.6-112.5)
Female	2	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.3	nc	(nc-nc)
Male	6	5.5	109.9	(40.1-239.3)	Female	3	1.5	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	6	7.3	81.7	(29.8-177.8)
Male	6	3.9	154.7	(56.5-336.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.0	nc	(nc-nc)	Female	6	9.5	63.2	(23.1-137.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.4	nc	(nc-nc)	Male	125	123.1	101.6	(84.5-121.0)
Female	0	1.3	nc	(nc-nc)	Female	118	139.8	84.4	(69.9-101.1)
<u>Lung and Bronchus</u>									
Male	20	17.1	116.7	(71.3-180.2)					
Female	20	20.0	100.1	(61.1-154.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	35.2	96.7	(66.9-135.1)	Male	20	22.1	90.6	(55.3-140.0)
Female	8	13.7	58.6	(25.2-115.4)	Female	15	18.0	83.5	(46.7-137.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.3	78.8	(25.4-183.8)	Male	10	7.1	139.9	(67.0-257.3)
Female	5	5.7	87.2	(28.1-203.4)	Female	7	6.3	111.2	(44.5-229.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	20	19.5	102.5	(62.6-158.4)
Female	141	143.2	98.4	(82.9-116.1)	Female	20	18.3	109.4	(66.8-169.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	4.5	132.5	(48.4-288.4)	Male	24	16.3	147.2	(94.3-219.0)
<u>Colon / Rectum</u>					Female	12	8.0	149.6	(77.2-261.3)
Male	38	36.1	105.2	(74.5-144.5)	<u>Ovary</u>				
Female	34	38.8	87.7	(60.7-122.5)	Female	7	12.5	56.1	(22.5-115.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	8.8	nc	(nc-nc)	Male	8	12.9	61.9	(26.6-121.9)
Female	4	2.6	nc	(nc-nc)	Female	17	14.4	118.2	(68.8-189.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.3	nc	(nc-nc)	Male	87	106.1	82.0	(65.7-101.2)
Female	2	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	8.2	97.9	(42.2-192.9)
Male	28	19.8	141.2	(93.8-204.0)	Female	4	5.5	nc	(nc-nc)
Female	11	11.6	94.7	(47.2-169.5)	<u>Testis</u>				
<u>Larynx</u>					Male	1	4.0	nc	(nc-nc)
Male	7	5.1	136.7	(54.8-281.7)	<u>Thyroid</u>				
Female	1	1.6	nc	(nc-nc)	Male	3	8.4	nc	(nc-nc)
<u>Leukemia</u>					Female	20	25.0	80.0	(48.8-123.5)
Male	16	13.8	115.7	(66.1-188.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	10.7	65.3	(26.1-134.5)	Female	27	32.6	82.8	(54.5-120.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	12.3	106.1	(56.4-181.5)	Male	432	442.0	97.7	(88.7-107.4)
Female	5	4.5	111.3	(35.9-259.8)	Female	481	490.0	98.2	(89.6-107.3)
<u>Lung and Bronchus</u>									
Male	72	61.5	117.0	(91.5-147.3)					
Female	88	69.7	126.3	(101.3-155.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	5	3.3	150.6	(48.5-351.4)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	12.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	8	11.0	72.7	(31.3-143.2)
<u>Lung and Bronchus</u>									
Male	0	1.9	nc	(nc-nc)					
Female	0	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	16.3	92.1	(51.5-151.9)	Male	6	11.1	53.9	(19.7-117.4)
Female	11	6.8	160.9	(80.2-287.9)	Female	4	9.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.4	145.2	(46.8-339.0)	Male	2	3.5	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	0	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	17	9.8	172.9	(100.6-276.8)
Female	78	81.0	96.3	(76.1-120.2)	Female	11	9.6	114.9	(57.3-205.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	10	8.7	114.3	(54.7-210.3)
<u>Colon / Rectum</u>					Female	3	4.3	nc	(nc-nc)
Male	16	18.0	88.9	(50.8-144.4)	<u>Ovary</u>				
Female	20	19.6	101.9	(62.2-157.5)	Female	6	6.9	87.3	(31.9-190.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.4	nc	(nc-nc)	Male	7	6.3	111.4	(44.6-229.5)
Female	2	1.4	nc	(nc-nc)	Female	4	7.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.4	nc	(nc-nc)	Male	70	53.8	130.0	(101.4-164.3)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.0	125.5	(40.5-293.0)
Male	3	10.5	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
Female	7	6.4	110.2	(44.1-227.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.7	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	7	5.0	139.6	(55.9-287.7)
<u>Leukemia</u>					Female	18	15.1	119.5	(70.8-188.8)
Male	9	7.0	129.0	(58.9-245.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.4	91.9	(29.6-214.5)	Female	18	18.6	96.6	(57.2-152.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	6.4	124.8	(53.7-245.8)	Male	234	221.7	105.6	(92.5-120.0)
Female	0	2.3	nc	(nc-nc)	Female	248	265.2	93.5	(82.3-105.9)
<u>Lung and Bronchus</u>									
Male	29	29.1	99.7	(66.8-143.3)					
Female	43	36.6	117.5	(85.1-158.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	19.8	85.8	(50.0-137.4)	Male	11	12.7	86.7	(43.2-155.1)
Female	3	7.6	nc	(nc-nc)	Female	12	10.3	116.0	(59.9-202.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	1	5.0	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	9	12.0	74.8	(34.1-142.0)
Female	78	79.7	97.8	(77.3-122.1)	Female	8	10.7	74.9	(32.3-147.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.5	nc	(nc-nc)	Male	8	9.5	84.5	(36.4-166.6)
<u>Colon / Rectum</u>					Female	4	4.7	nc	(nc-nc)
Male	18	20.5	87.7	(52.0-138.7)	<u>Ovary</u>				
Female	23	21.1	108.8	(69.0-163.3)	Female	12	7.4	161.4	(83.3-282.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	5.0	nc	(nc-nc)	Male	11	7.3	150.5	(75.0-269.3)
Female	0	1.4	nc	(nc-nc)	Female	8	7.8	103.0	(44.4-203.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.6	nc	(nc-nc)	Male	43	60.1	71.5	(51.8-96.4)
Female	0	2.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	4.6	nc	(nc-nc)
Male	2	11.4	nc	(nc-nc)	Female	0	3.0	nc	(nc-nc)
Female	7	6.6	106.1	(42.5-218.6)	<u>Testis</u>				
<u>Larynx</u>					Male	0	3.6	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	5	5.3	94.7	(30.5-221.0)
<u>Leukemia</u>					Female	4	15.9	nc	(nc-nc)
Male	7	9.8	71.1	(28.5-146.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	6.8	nc	(nc-nc)	Female	17	18.5	91.8	(53.4-146.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	7.1	nc	(nc-nc)	Male	171	261.4	65.4	(56.0-76.0)
Female	0	2.6	nc	(nc-nc)	Female	219	281.4	77.8	(67.8-88.8)
<u>Lung and Bronchus</u>									
Male	14	35.0	40.0	(21.8-67.1)					
Female	19	38.8	49.0	(29.5-76.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	39.6	73.3	(49.0-105.2)	Male	27	25.4	106.2	(70.0-154.5)
Female	12	12.5	95.8	(49.4-167.4)	Female	25	18.8	132.9	(86.0-196.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.4	107.4	(46.3-211.7)	Male	5	8.3	60.5	(19.5-141.3)
Female	5	6.1	81.4	(26.2-189.9)	Female	13	6.0	216.7	(115.3-370.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.4	nc	(nc-nc)	Male	30	22.5	133.5	(90.0-190.5)
Female	170	156.3	108.7	(93.0-126.4)	Female	16	17.9	89.2	(51.0-144.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.3	nc	(nc-nc)	Male	17	19.1	88.9	(51.7-142.3)
<u>Colon / Rectum</u>					Female	3	8.1	nc	(nc-nc)
Male	28	42.0	66.6	(44.2-96.3)	<u>Ovary</u>				
Female	38	37.3	101.9	(72.1-139.9)	Female	11	13.1	84.2	(42.0-150.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	10.1	79.3	(34.1-156.2)	Male	14	14.7	95.3	(52.1-159.9)
Female	7	2.5	280.6	(112.4-578.2)	Female	11	13.1	83.9	(41.8-150.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.6	nc	(nc-nc)	Male	104	119.8	86.8	(71.0-105.2)
Female	1	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	9.3	64.2	(23.4-139.7)
Male	22	23.2	94.7	(59.3-143.4)	Female	4	5.2	nc	(nc-nc)
Female	11	12.0	91.5	(45.6-163.7)	<u>Testis</u>				
<u>Larynx</u>					Male	8	4.6	173.1	(74.5-341.1)
Male	3	5.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.7	nc	(nc-nc)	Male	18	10.1	178.8	(105.9-282.6)
<u>Leukemia</u>					Female	45	29.7	151.4	(110.4-202.6)
Male	18	15.8	114.0	(67.5-180.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	10.5	104.6	(52.1-187.2)	Female	22	34.7	63.4	(39.7-96.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	14.0	50.1	(20.1-103.2)	Male	429	505.3	84.9	(77.1-93.3)
Female	2	4.3	nc	(nc-nc)	Female	482	502.8	95.9	(87.5-104.8)
<u>Lung and Bronchus</u>									
Male	38	69.7	54.5	(38.6-74.8)					
Female	41	67.0	61.2	(43.9-83.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	5	6.6	75.2	(24.2-175.5)
<u>Lung and Bronchus</u>									
Male	0	0.6	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	48	47.6	100.9	(74.4-133.8)	Male	24	30.3	79.2	(50.7-117.8)
Female	14	19.7	71.0	(38.8-119.1)	Female	29	26.8	108.1	(72.4-155.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	8.9	135.3	(69.8-236.3)	Male	10	9.6	104.6	(50.1-192.4)
Female	11	8.5	129.8	(64.7-232.2)	Female	4	9.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.6	nc	(nc-nc)	Male	24	26.9	89.3	(57.2-132.8)
Female	206	207.3	99.4	(86.3-113.9)	Female	34	26.6	127.9	(88.6-178.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.9	72.5	(23.4-169.2)	Male	16	21.8	73.6	(42.0-119.5)
<u>Colon / Rectum</u>					Female	14	11.6	120.2	(65.7-201.7)
Male	45	50.0	90.0	(65.7-120.5)	<u>Ovary</u>				
Female	56	57.0	98.3	(74.2-127.6)	Female	23	18.3	126.0	(79.9-189.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	11.5	77.9	(35.6-148.0)	Male	18	17.4	103.6	(61.4-163.8)
Female	4	3.8	nc	(nc-nc)	Female	18	20.8	86.3	(51.1-136.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.4	145.1	(46.8-338.6)	Male	141	134.1	105.2	(88.5-124.0)
Female	5	3.3	153.8	(49.6-358.9)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	11.1	117.5	(62.5-200.9)
Male	27	26.7	101.3	(66.7-147.4)	Female	9	8.0	112.2	(51.2-213.1)
Female	14	16.9	82.9	(45.3-139.1)	<u>Testis</u>				
<u>Larynx</u>					Male	9	7.0	128.6	(58.7-244.2)
Male	6	6.7	89.6	(32.7-195.0)	<u>Thyroid</u>				
Female	3	2.3	nc	(nc-nc)	Male	15	12.3	122.2	(68.3-201.5)
<u>Leukemia</u>					Female	44	38.4	114.5	(83.2-153.7)
Male	21	19.1	110.1	(68.1-168.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	16.0	68.6	(34.2-122.8)	Female	48	46.8	102.5	(75.6-135.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	16.1	93.2	(52.1-153.7)	Male	573	591.6	96.9	(89.1-105.1)
Female	4	6.5	nc	(nc-nc)	Female	693	713.9	97.1	(90.0-104.6)
<u>Lung and Bronchus</u>									
Male	66	81.0	81.5	(63.0-103.6)					
Female	84	99.4	84.5	(67.4-104.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.3	112.9	(41.2-245.8)	Male	3	3.9	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	18	29.2	61.7	(36.6-97.6)	Female	0	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.5	nc	(nc-nc)
Male	4	6.3	nc	(nc-nc)	<u>Ovary</u>				
Female	8	6.2	129.2	(55.6-254.7)	Female	3	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.7	nc	(nc-nc)	Male	5	2.2	224.4	(72.3-523.7)
Female	1	0.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	19	22.1	85.9	(51.7-134.2)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.4	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.6	89.3	(28.8-208.4)
Male	5	2.4	210.3	(67.8-490.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.7	nc	(nc-nc)	Female	5	6.9	72.9	(23.5-170.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.4	nc	(nc-nc)	Male	79	81.5	97.0	(76.8-120.8)
Female	0	0.8	nc	(nc-nc)	Female	63	90.6	69.6	(53.4-89.0)
<u>Lung and Bronchus</u>									
Male	6	10.1	59.3	(21.6-129.0)					
Female	4	11.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.7	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	13	14.6	88.9	(47.3-152.0)	Female	0	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.8	nc	(nc-nc)
Male	3	4.1	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	7	11.5	60.8	(24.4-125.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	0.9	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.7	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.9	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.4	nc	(nc-nc)	Male	44	48.1	91.4	(66.4-122.7)
Female	1	0.4	nc	(nc-nc)	Female	45	46.5	96.7	(70.5-129.4)
<u>Lung and Bronchus</u>									
Male	3	6.3	nc	(nc-nc)					
Female	4	6.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	1.8	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	5	9.3	53.9	(17.4-125.7)	Female	0	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	6.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	21	25.8	81.4	(50.4-124.4)
Female	0	0.3	nc	(nc-nc)	Female	18	30.1	59.7	(35.4-94.4)
<u>Lung and Bronchus</u>									
Male	2	3.4	nc	(nc-nc)					
Female	1	4.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	15.4	110.3	(64.2-176.6)	Male	7	10.6	66.2	(26.5-136.3)
Female	4	5.9	nc	(nc-nc)	Female	5	9.2	54.1	(17.4-126.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.4	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	8	9.4	85.4	(36.8-168.2)
Female	80	76.1	105.2	(83.4-130.9)	Female	8	8.6	93.2	(40.1-183.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	6	8.4	71.7	(26.2-156.1)
<u>Colon / Rectum</u>					Female	5	3.9	126.8	(40.9-295.8)
Male	12	17.3	69.5	(35.9-121.5)	<u>Ovary</u>				
Female	21	17.2	121.8	(75.3-186.2)	Female	8	6.4	125.5	(54.0-247.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	4.2	168.3	(67.4-346.8)	Male	3	6.0	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	6	6.1	98.4	(35.9-214.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	44	51.5	85.4	(62.0-114.6)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.8	nc	(nc-nc)
Male	4	10.1	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
Female	1	5.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.6	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
<u>Leukemia</u>					Female	16	15.0	106.5	(60.8-173.0)
Male	5	6.7	74.9	(24.2-174.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.1	118.3	(43.2-257.6)	Female	15	17.6	85.5	(47.8-141.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.0	82.8	(26.7-193.3)	Male	162	211.6	76.6	(65.2-89.3)
Female	3	2.1	nc	(nc-nc)	Female	238	243.2	97.9	(85.8-111.1)
<u>Lung and Bronchus</u>									
Male	19	27.8	68.2	(41.1-106.6)					
Female	36	32.0	112.6	(78.9-156.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	14.9	134.2	(82.0-207.3)	Male	7	9.5	73.3	(29.4-151.1)
Female	1	4.6	nc	(nc-nc)	Female	4	6.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	3	8.4	nc	(nc-nc)
Female	43	52.5	81.9	(59.3-110.3)	Female	6	6.4	93.7	(34.2-203.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.7	nc	(nc-nc)	Male	6	7.2	83.2	(30.4-181.2)
<u>Colon / Rectum</u>					Female	2	2.9	nc	(nc-nc)
Male	18	15.2	118.5	(70.2-187.3)	<u>Ovary</u>				
Female	16	13.5	118.3	(67.6-192.2)	Female	4	4.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.9	154.4	(56.4-336.0)	Male	5	5.6	89.6	(28.9-209.1)
Female	0	0.9	nc	(nc-nc)	Female	6	4.9	123.4	(45.1-268.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	30	47.4	63.2	(42.7-90.3)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.5	nc	(nc-nc)
Male	13	8.7	149.8	(79.7-256.2)	Female	1	1.9	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	9	9.6	94.1	(42.9-178.6)
Male	1	5.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.8	158.1	(57.7-344.1)	Female	19	11.9	159.1	(95.7-248.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.5	109.2	(39.9-237.7)	Male	180	192.3	93.6	(80.4-108.3)
Female	2	1.6	nc	(nc-nc)	Female	174	174.9	99.5	(85.2-115.4)
<u>Lung and Bronchus</u>									
Male	33	26.9	122.6	(84.4-172.2)					
Female	32	23.9	134.1	(91.7-189.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	42.0	102.4	(74.1-138.0)	Male	29	28.3	102.6	(68.7-147.3)
Female	19	15.1	126.2	(76.0-197.1)	Female	23	22.8	101.0	(64.0-151.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	8.8	113.9	(54.5-209.4)	Male	5	9.0	55.7	(17.9-130.0)
Female	4	7.4	nc	(nc-nc)	Female	7	7.2	97.4	(39.0-200.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.5	nc	(nc-nc)	Male	15	25.0	59.9	(33.5-98.8)
Female	197	183.1	107.6	(93.1-123.7)	Female	19	21.5	88.4	(53.2-138.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	6.4	nc	(nc-nc)	Male	22	21.6	101.8	(63.8-154.2)
<u>Colon / Rectum</u>					Female	8	9.7	82.6	(35.6-162.7)
Male	51	46.1	110.5	(82.3-145.3)	<u>Ovary</u>				
Female	42	44.2	95.1	(68.5-128.5)	Female	18	15.5	115.8	(68.6-183.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	11.0	127.4	(69.6-213.7)	Male	23	15.9	144.6	(91.6-216.9)
Female	4	3.0	nc	(nc-nc)	Female	18	15.7	114.9	(68.0-181.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	3.5	226.6	(97.6-446.5)	Male	133	131.0	101.5	(85.0-120.3)
Female	2	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	10.2	68.9	(27.6-142.0)
Male	21	26.3	79.9	(49.5-122.2)	Female	10	6.2	160.4	(76.8-294.9)
Female	9	14.3	63.0	(28.7-119.5)	<u>Testis</u>				
<u>Larynx</u>					Male	11	7.0	156.6	(78.1-280.3)
Male	11	6.4	171.3	(85.4-306.5)	<u>Thyroid</u>				
Female	3	2.0	nc	(nc-nc)	Male	13	12.6	103.5	(55.1-177.1)
<u>Leukemia</u>					Female	26	36.5	71.2	(46.5-104.4)
Male	16	17.8	89.9	(51.3-145.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	12.7	78.7	(37.7-144.8)	Female	45	41.1	109.4	(79.8-146.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	15.4	71.2	(35.5-127.4)	Male	577	557.8	103.4	(95.2-112.2)
Female	9	5.1	174.9	(79.8-332.0)	Female	623	598.8	104.0	(96.0-112.5)
<u>Lung and Bronchus</u>									
Male	94	74.7	125.9	(101.7-154.1)					
Female	86	80.2	107.3	(85.8-132.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	20.3	133.1	(87.7-193.6)	Male	19	12.6	151.0	(90.9-235.8)
Female	11	8.3	133.2	(66.4-238.4)	Female	11	10.5	104.5	(52.1-186.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.5	141.3	(45.5-329.8)	Male	4	4.1	nc	(nc-nc)
Female	6	3.4	177.8	(64.9-387.0)	Female	8	3.8	213.0	(91.7-419.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	11	11.2	98.5	(49.1-176.2)
Female	86	84.3	102.0	(81.6-125.9)	Female	12	11.0	109.2	(56.4-190.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.6	nc	(nc-nc)	Male	10	8.9	112.0	(53.6-206.0)
<u>Colon / Rectum</u>					Female	1	4.7	nc	(nc-nc)
Male	19	20.9	90.9	(54.7-142.0)	<u>Ovary</u>				
Female	21	23.2	90.5	(56.0-138.3)	Female	7	7.3	95.7	(38.4-197.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.9	102.2	(32.9-238.5)	Male	6	7.3	81.7	(29.8-177.9)
Female	2	1.6	nc	(nc-nc)	Female	6	8.6	69.6	(25.4-151.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	57	56.4	101.1	(76.6-131.0)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.7	nc	(nc-nc)
Male	8	11.0	72.8	(31.3-143.4)	Female	4	3.3	nc	(nc-nc)
Female	5	6.9	72.7	(23.4-169.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.3	nc	(nc-nc)
Male	8	2.9	280.5	(120.8-552.8)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	5	4.7	106.5	(34.3-248.4)
<u>Leukemia</u>					Female	9	14.2	63.4	(28.9-120.3)
Male	4	7.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	6.3	158.3	(75.8-291.2)	Female	17	19.0	89.6	(52.2-143.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	6.7	104.8	(42.0-216.0)	Male	253	247.0	102.4	(90.2-115.8)
Female	0	2.7	nc	(nc-nc)	Female	290	290.0	100.0	(88.8-112.2)
<u>Lung and Bronchus</u>									
Male	32	34.8	92.0	(62.9-129.9)					
Female	49	42.1	116.3	(86.0-153.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.9	135.5	(58.3-266.9)	Male	4	3.6	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	9	3.2	281.3	(128.4-534.1)
Female	24	22.1	108.6	(69.6-161.6)	Female	2	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.2	nc	(nc-nc)
Male	7	6.0	116.1	(46.5-239.2)	<u>Ovary</u>				
Female	5	5.7	87.1	(28.1-203.2)	Female	2	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.4	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	9	16.7	53.8	(24.5-102.1)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.7	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.6	nc	(nc-nc)	Female	3	5.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.9	nc	(nc-nc)	Male	71	71.7	99.0	(77.3-124.8)
Female	0	0.7	nc	(nc-nc)	Female	69	75.7	91.2	(71.0-115.4)
<u>Lung and Bronchus</u>									
Male	12	10.0	120.2	(62.0-209.9)					
Female	14	11.4	122.5	(66.9-205.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.1	127.4	(58.1-241.9)	Male	4	5.1	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	4.5	nc	(nc-nc)
Female	37	29.8	124.2	(87.4-171.2)	Female	3	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.6	nc	(nc-nc)
Male	10	8.0	125.7	(60.2-231.2)	<u>Ovary</u>				
Female	14	7.4	189.7	(103.6-318.2)	Female	3	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	2.0	301.0	(109.9-655.1)	Male	5	2.8	178.2	(57.4-415.9)
Female	0	0.5	nc	(nc-nc)	Female	6	2.6	233.9	(85.4-509.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	24	23.9	100.2	(64.2-149.2)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	2	4.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.3	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.5	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.1	nc	(nc-nc)	Female	13	6.4	201.8	(107.4-345.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	2.9	nc	(nc-nc)	Male	104	99.6	104.4	(85.3-126.5)
Female	0	0.8	nc	(nc-nc)	Female	125	98.5	126.9	(105.6-151.2)
<u>Lung and Bronchus</u>									
Male	19	13.2	144.4	(86.9-225.4)					
Female	19	13.1	145.4	(87.5-227.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	90	73.2	122.9	(98.8-151.0)	Male	69	43.7	157.9	(122.9-199.9)
Female	28	24.0	116.6	(77.5-168.5)	Female	40	29.8	134.1	(95.8-182.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	11.6	137.4	(78.5-223.2)	Male	10	14.3	69.9	(33.5-128.5)
Female	10	9.6	104.3	(49.9-191.8)	Female	14	10.9	128.5	(70.2-215.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	2.4	206.9	(66.7-482.7)	Male	44	38.4	114.7	(83.3-154.0)
Female	310	246.8	125.6	(112.0-140.4)	Female	42	31.4	133.6	(96.3-180.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	7.1	84.9	(31.0-184.8)	Male	34	30.7	110.9	(76.8-155.0)
<u>Colon / Rectum</u>					Female	15	13.8	108.8	(60.9-179.5)
Male	56	70.8	79.1	(59.8-102.8)	<u>Ovary</u>				
Female	60	64.6	92.9	(70.9-119.6)	Female	20	21.4	93.3	(57.0-144.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	24	17.6	136.2	(87.2-202.6)	Male	29	26.1	111.1	(74.4-159.5)
Female	3	4.7	nc	(nc-nc)	Female	18	24.7	72.8	(43.1-115.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.8	nc	(nc-nc)	Male	195	206.6	94.4	(81.6-108.6)
Female	0	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	16.4	91.3	(51.1-150.6)
Male	32	37.5	85.3	(58.3-120.4)	Female	13	9.1	142.1	(75.6-243.1)
Female	15	20.4	73.6	(41.1-121.3)	<u>Testis</u>				
<u>Larynx</u>					Male	4	5.9	nc	(nc-nc)
Male	5	10.1	49.5	(15.9-115.4)	<u>Thyroid</u>				
Female	0	2.9	nc	(nc-nc)	Male	12	14.4	83.2	(43.0-145.4)
<u>Leukemia</u>					Female	26	38.8	66.9	(43.7-98.1)
Male	33	27.1	121.8	(83.8-171.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	29	18.0	161.5	(108.1-231.9)	Female	45	58.1	77.5	(56.5-103.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	31	23.9	129.6	(88.1-184.0)	Male	884	871.9	101.4	(94.8-108.3)
Female	7	7.9	89.0	(35.7-183.5)	Female	872	842.9	103.4	(96.7-110.6)
<u>Lung and Bronchus</u>									
Male	95	126.7	75.0	(60.6-91.6)					
Female	107	127.6	83.9	(68.7-101.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.7	87.3	(28.1-203.7)	Male	1	3.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	6	3.2	190.0	(69.4-413.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	19	25.5	74.4	(44.8-116.2)	Female	1	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	10	6.1	163.0	(78.0-299.7)	<u>Ovary</u>				
Female	1	6.7	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.5	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	18.5	70.2	(37.3-120.0)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.4	nc	(nc-nc)
Male	0	3.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	4.6	nc	(nc-nc)
Male	0	2.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.8	nc	(nc-nc)	Female	6	5.8	103.8	(37.9-225.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.2	nc	(nc-nc)	Male	55	75.4	72.9	(54.9-94.9)
Female	0	0.8	nc	(nc-nc)	Female	60	84.9	70.7	(53.9-91.0)
<u>Lung and Bronchus</u>									
Male	7	10.0	69.9	(28.0-144.0)					
Female	6	11.2	53.5	(19.5-116.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.1	162.7	(52.4-379.7)	Male	1	1.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	8	10.2	78.5	(33.8-154.7)	Female	2	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	9.5	52.5	(16.9-122.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.6	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	5	2.4	206.9	(66.7-482.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.1	nc	(nc-nc)	Male	33	38.3	86.0	(59.2-120.9)
Female	0	0.3	nc	(nc-nc)	Female	27	33.6	80.3	(52.9-116.8)
<u>Lung and Bronchus</u>									
Male	3	5.6	nc	(nc-nc)					
Female	4	5.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	19.6	117.3	(74.3-176.0)	Male	14	12.0	116.3	(63.5-195.1)
Female	6	5.9	101.3	(37.0-220.4)	Female	11	8.1	136.5	(68.1-244.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.3	153.0	(49.3-357.1)	Male	6	3.8	159.6	(58.3-347.4)
Female	0	2.6	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	15	10.5	143.3	(80.1-236.3)
Female	71	64.1	110.8	(86.5-139.8)	Female	7	8.0	87.6	(35.1-180.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.1	nc	(nc-nc)	Male	7	8.1	86.2	(34.5-177.6)
<u>Colon / Rectum</u>					Female	3	3.5	nc	(nc-nc)
Male	16	19.9	80.5	(46.0-130.7)	<u>Ovary</u>				
Female	14	17.2	81.3	(44.4-136.5)	Female	5	5.5	90.4	(29.1-211.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.5	nc	(nc-nc)	Male	8	6.9	115.9	(49.9-228.5)
Female	2	1.1	nc	(nc-nc)	Female	5	6.2	81.0	(26.1-189.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	58	47.8	121.4	(92.2-156.9)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.4	135.8	(49.6-295.5)
Male	7	10.0	69.9	(28.0-144.0)	Female	3	2.4	nc	(nc-nc)
Female	1	5.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.1	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	10	11.8	84.9	(40.7-156.2)
Male	7	7.5	92.8	(37.2-191.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.8	104.8	(33.8-244.6)	Female	6	13.8	43.4	(15.9-94.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	6.1	98.7	(36.0-214.8)	Male	224	227.9	98.3	(85.8-112.0)
Female	1	1.9	nc	(nc-nc)	Female	189	216.6	87.3	(75.3-100.6)
<u>Lung and Bronchus</u>									
Male	24	33.1	72.6	(46.5-108.0)					
Female	27	30.4	88.9	(58.6-129.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	14.4	48.8	(19.5-100.5)	Male	6	9.9	60.5	(22.1-131.6)
Female	3	5.0	nc	(nc-nc)	Female	6	7.9	76.0	(27.8-165.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.1	195.4	(71.4-425.4)	Male	5	3.2	157.1	(50.6-366.5)
Female	0	2.6	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	7	8.7	80.3	(32.2-165.5)
Female	70	65.4	107.0	(83.4-135.2)	Female	14	7.3	190.9	(104.3-320.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.3	nc	(nc-nc)	Male	6	8.1	74.4	(27.2-162.0)
<u>Colon / Rectum</u>					Female	5	3.3	149.4	(48.1-348.6)
Male	15	16.1	93.3	(52.2-153.9)	<u>Ovary</u>				
Female	14	14.9	94.3	(51.5-158.2)	Female	4	5.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.0	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	10	5.2	192.4	(92.1-353.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	51	50.5	101.0	(75.2-132.9)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.6	nc	(nc-nc)
Male	7	9.6	73.0	(29.2-150.4)	Female	4	2.1	nc	(nc-nc)
Female	3	5.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.0	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	9	12.9	69.7	(31.8-132.3)
Male	5	6.1	81.4	(26.2-190.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.3	nc	(nc-nc)	Female	22	14.7	149.3	(93.5-226.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.8	nc	(nc-nc)	Male	155	200.4	77.3	(65.6-90.5)
Female	1	1.8	nc	(nc-nc)	Female	207	208.2	99.4	(86.3-113.9)
<u>Lung and Bronchus</u>									
Male	13	26.7	48.7	(25.9-83.3)					
Female	20	27.5	72.7	(44.4-112.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	14.4	97.5	(53.3-163.6)	Male	11	9.9	110.9	(55.3-198.4)
Female	3	5.0	nc	(nc-nc)	Female	9	7.9	114.0	(52.0-216.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.1	nc	(nc-nc)	Male	8	3.2	251.3	(108.2-495.2)
Female	5	2.6	195.7	(63.1-456.8)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	19	8.7	218.0	(131.2-340.4)
Female	74	65.4	113.1	(88.8-142.0)	Female	10	7.3	136.4	(65.3-250.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	7	8.1	86.8	(34.8-178.9)
<u>Colon / Rectum</u>					Female	1	3.3	nc	(nc-nc)
Male	21	16.1	130.6	(80.8-199.6)	<u>Ovary</u>				
Female	17	14.9	114.5	(66.6-183.3)	Female	4	5.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.0	nc	(nc-nc)	Male	8	5.7	141.4	(60.9-278.6)
Female	2	1.0	nc	(nc-nc)	Female	13	5.2	250.1	(133.0-427.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	74	50.5	146.6	(115.1-184.1)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.6	140.4	(45.2-327.6)
Male	10	9.6	104.3	(49.9-191.8)	Female	1	2.1	nc	(nc-nc)
Female	5	5.0	99.9	(32.2-233.0)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.0	nc	(nc-nc)
Male	0	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	5	4.3	115.4	(37.2-269.2)
<u>Leukemia</u>					Female	17	12.9	131.7	(76.7-210.8)
Male	5	6.1	81.4	(26.2-190.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.3	164.5	(65.9-338.9)	Female	16	14.7	108.6	(62.0-176.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.8	85.8	(27.7-200.2)	Male	250	200.4	124.7	(109.7-141.2)
Female	0	1.8	nc	(nc-nc)	Female	226	208.2	108.6	(94.9-123.7)
<u>Lung and Bronchus</u>									
Male	30	26.7	112.4	(75.8-160.5)					
Female	27	27.5	98.1	(64.6-142.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	29.3	81.9	(52.5-121.9)	Male	18	18.3	98.4	(58.3-155.5)
Female	4	10.5	nc	(nc-nc)	Female	7	14.8	47.4	(19.0-97.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.2	114.5	(41.8-249.2)	Male	3	5.9	nc	(nc-nc)
Female	2	4.8	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	1.0	498.5	(160.7-1163.4)	Male	17	16.2	104.9	(61.1-168.0)
Female	129	118.2	109.1	(91.1-129.7)	Female	9	14.5	62.3	(28.4-118.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.0	nc	(nc-nc)	Male	5	13.0	38.4	(12.4-89.6)
<u>Colon / Rectum</u>					Female	9	6.4	141.3	(64.5-268.3)
Male	24	30.1	79.6	(51.0-118.5)	<u>Ovary</u>				
Female	25	30.5	81.9	(53.0-121.0)	Female	14	10.1	138.3	(75.5-232.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	7.1	nc	(nc-nc)	Male	11	10.6	103.7	(51.7-185.6)
Female	5	2.0	244.0	(78.6-569.4)	Female	11	11.0	99.8	(49.7-178.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.9	nc	(nc-nc)	Male	77	82.2	93.7	(73.9-117.1)
Female	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.8	74.1	(23.9-172.8)
Male	12	16.0	74.8	(38.6-130.7)	Female	6	4.3	140.4	(51.3-305.5)
Female	7	9.4	74.4	(29.8-153.2)	<u>Testis</u>				
<u>Larynx</u>					Male	7	3.7	188.1	(75.4-387.6)
Male	2	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	6	7.1	84.8	(30.9-184.5)
<u>Leukemia</u>					Female	25	22.1	113.0	(73.1-166.8)
Male	5	11.5	43.6	(14.0-101.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.6	58.1	(18.7-135.6)	Female	24	26.2	91.7	(58.7-136.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	9.7	51.8	(16.7-120.8)	Male	300	359.2	83.5	(74.3-93.5)
Female	1	3.5	nc	(nc-nc)	Female	354	395.4	89.5	(80.4-99.3)
<u>Lung and Bronchus</u>									
Male	39	50.1	77.9	(55.4-106.5)					
Female	41	54.9	74.6	(53.6-101.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	7.2	nc	(nc-nc)	Male	5	4.8	104.9	(33.8-244.7)
Female	0	1.6	nc	(nc-nc)	Female	5	3.0	164.2	(52.9-383.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	4.2	nc	(nc-nc)
Female	24	25.8	93.0	(59.6-138.4)	Female	6	2.6	227.6	(83.1-495.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.2	nc	(nc-nc)
Male	10	7.6	131.9	(63.2-242.7)	<u>Ovary</u>				
Female	7	5.1	137.4	(55.0-283.0)	Female	0	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.9	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	15	23.5	63.8	(35.7-105.2)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.7	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.8	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.5	nc	(nc-nc)	Female	8	5.7	140.4	(60.5-276.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.7	nc	(nc-nc)	Male	73	95.9	76.1	(59.7-95.7)
Female	0	0.6	nc	(nc-nc)	Female	77	77.9	98.9	(78.0-123.6)
<u>Lung and Bronchus</u>									
Male	13	13.3	97.5	(51.9-166.7)					
Female	4	9.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.8	nc	(nc-nc)	Male	6	2.9	210.1	(76.7-457.3)
Female	1	1.3	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	16	15.0	107.0	(61.1-173.8)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.8	nc	(nc-nc)
Male	3	4.8	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.5	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.1	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.3	nc	(nc-nc)	Male	11	13.1	84.1	(41.9-150.5)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.6	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.0	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	54	56.6	95.4	(71.6-124.4)
Female	0	0.4	nc	(nc-nc)	Female	40	48.4	82.6	(59.0-112.5)
<u>Lung and Bronchus</u>									
Male	8	8.1	99.0	(42.6-195.0)					
Female	5	6.8	73.0	(23.5-170.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.8	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	2.0	255.4	(82.3-596.1)
Female	14	12.3	113.7	(62.1-190.8)	Female	3	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	5	3.7	134.8	(43.5-314.7)	<u>Ovary</u>				
Female	3	3.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	10.2	98.2	(47.0-180.6)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.0	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	35	43.8	79.8	(55.6-111.0)
Female	1	0.4	nc	(nc-nc)	Female	42	40.5	103.8	(74.8-140.3)
<u>Lung and Bronchus</u>									
Male	5	6.3	79.5	(25.6-185.5)					
Female	5	5.8	85.5	(27.6-199.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	49	42.2	116.1	(85.9-153.5)	Male	38	26.9	141.3	(100.0-193.9)
Female	19	16.7	114.1	(68.6-178.1)	Female	27	23.0	117.1	(77.2-170.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	8.0	125.2	(59.9-230.2)	Male	10	8.6	116.7	(55.8-214.5)
Female	5	7.6	65.7	(21.2-153.4)	Female	6	7.7	77.5	(28.3-168.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.5	nc	(nc-nc)	Male	26	23.8	109.2	(71.3-160.0)
Female	177	183.9	96.2	(82.6-111.5)	Female	19	22.7	83.6	(50.3-130.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	6.0	100.8	(36.8-219.4)	Male	26	19.9	130.5	(85.2-191.2)
<u>Colon / Rectum</u>					Female	12	10.2	117.7	(60.8-205.7)
Male	37	43.8	84.5	(59.5-116.5)	<u>Ovary</u>				
Female	51	47.5	107.3	(79.9-141.1)	Female	12	15.9	75.3	(38.9-131.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	10.6	94.0	(45.0-172.8)	Male	18	15.6	115.5	(68.4-182.6)
Female	4	3.3	nc	(nc-nc)	Female	19	17.6	108.0	(65.0-168.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	3.1	nc	(nc-nc)	Male	137	128.5	106.6	(89.5-126.1)
Female	2	3.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	9.9	nc	(nc-nc)
Male	29	24.2	119.9	(80.3-172.3)	Female	3	6.7	nc	(nc-nc)
Female	13	14.7	88.5	(47.1-151.3)	<u>Testis</u>				
<u>Larynx</u>					Male	7	5.8	121.6	(48.7-250.5)
Male	6	6.2	97.5	(35.6-212.2)	<u>Thyroid</u>				
Female	2	2.1	nc	(nc-nc)	Male	20	10.8	185.5	(113.3-286.5)
<u>Leukemia</u>					Female	35	33.8	103.5	(72.1-143.9)
Male	24	17.0	140.8	(90.2-209.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	21	13.4	156.2	(96.7-238.9)	Female	33	42.3	78.0	(53.7-109.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	14.9	80.7	(41.6-140.9)	Male	604	537.3	112.4	(103.6-121.8)
Female	6	5.5	108.4	(39.6-236.0)	Female	633	620.7	102.0	(94.2-110.3)
<u>Lung and Bronchus</u>									
Male	80	73.6	108.8	(86.2-135.4)					
Female	95	86.4	109.9	(88.9-134.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	42.3	122.8	(91.7-161.1)	Male	26	28.4	91.7	(59.9-134.4)
Female	18	15.4	117.1	(69.4-185.1)	Female	27	22.0	122.9	(81.0-178.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	8.7	114.7	(54.9-211.0)	Male	8	9.1	88.2	(38.0-173.8)
Female	5	7.2	69.3	(22.3-161.7)	Female	9	7.2	125.5	(57.3-238.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.5	nc	(nc-nc)	Male	29	25.1	115.6	(77.4-166.0)
Female	195	177.5	109.8	(95.0-126.4)	Female	22	21.3	103.2	(64.6-156.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.9	100.9	(36.8-219.6)	Male	19	22.0	86.4	(52.0-134.9)
<u>Colon / Rectum</u>					Female	8	9.5	84.0	(36.2-165.6)
Male	37	46.6	79.4	(55.9-109.4)	<u>Ovary</u>				
Female	59	43.9	134.5	(102.4-173.5)	Female	11	15.1	72.8	(36.3-130.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	11.2	125.0	(68.3-209.7)	Male	11	16.1	68.5	(34.1-122.5)
Female	1	3.0	nc	(nc-nc)	Female	12	16.0	75.0	(38.7-131.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	3.5	170.8	(62.4-371.7)	Male	129	135.9	94.9	(79.2-112.8)
Female	2	2.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	10.2	68.3	(27.4-140.7)
Male	33	26.5	124.5	(85.7-174.9)	Female	8	6.2	129.9	(55.9-255.9)
Female	7	14.1	49.7	(19.9-102.5)	<u>Testis</u>				
<u>Larynx</u>					Male	5	6.9	72.8	(23.5-170.0)
Male	3	6.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	2.0	nc	(nc-nc)	Male	16	12.4	129.0	(73.7-209.6)
<u>Leukemia</u>					Female	40	33.7	118.7	(84.8-161.6)
Male	24	17.7	135.8	(87.0-202.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	20	12.6	159.2	(97.2-245.9)	Female	43	40.3	106.7	(77.2-143.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	15.9	75.6	(39.0-132.0)	Male	567	565.4	100.3	(92.2-108.9)
Female	3	5.1	nc	(nc-nc)	Female	644	588.8	109.4	(101.1-118.1)
<u>Lung and Bronchus</u>									
Male	82	75.3	108.9	(86.6-135.1)					
Female	108	82.0	131.8	(108.1-159.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	8.0	137.8	(68.7-246.6)	Male	6	5.6	107.9	(39.4-234.9)
Female	4	3.1	nc	(nc-nc)	Female	6	5.0	119.1	(43.5-259.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.7	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	30	41.7	72.0	(48.6-102.8)	Female	3	4.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	2.1	232.7	(75.0-543.1)
Male	9	9.1	99.1	(45.2-188.1)	<u>Ovary</u>				
Female	7	9.5	73.8	(29.5-152.0)	Female	6	3.5	173.0	(63.2-376.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.2	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	31	27.9	110.9	(75.4-157.5)
Female	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	1	5.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.2	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	4	8.3	nc	(nc-nc)
Male	4	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	2.7	262.8	(105.3-541.6)	Female	5	9.5	52.8	(17.0-123.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.4	nc	(nc-nc)	Male	122	112.0	109.0	(90.5-130.1)
Female	0	1.1	nc	(nc-nc)	Female	124	131.9	94.0	(78.2-112.1)
<u>Lung and Bronchus</u>									
Male	20	14.6	137.1	(83.7-211.8)					
Female	14	16.9	83.0	(45.3-139.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.4	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	7	5.7	123.8	(49.6-255.2)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	5.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.0	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	17	20.6	82.5	(48.1-132.2)
Female	0	0.2	nc	(nc-nc)	Female	22	17.8	123.6	(77.4-187.1)
<u>Lung and Bronchus</u>									
Male	2	2.6	nc	(nc-nc)					
Female	4	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.9	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.0	235.8	(94.5-485.9)
Female	29	21.2	137.0	(91.7-196.7)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	5	2.7	184.6	(59.5-430.7)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	4	5.6	nc	(nc-nc)	<u>Ovary</u>				
Female	8	4.3	186.6	(80.4-367.8)	Female	2	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	15	16.0	94.0	(52.6-155.1)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	5	3.2	155.1	(50.0-362.0)	Female	1	0.6	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.4	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.3	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.9	nc	(nc-nc)	Male	60	66.5	90.2	(68.8-116.1)
Female	0	0.5	nc	(nc-nc)	Female	64	64.3	99.6	(76.7-127.2)
<u>Lung and Bronchus</u>									
Male	2	8.7	nc	(nc-nc)					
Female	3	7.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	359	478.0	75.1	(67.5-83.3)	Male	238	320.2	74.3	(65.2-84.4)
Female	146	184.8	79.0	(66.7-92.9)	Female	223	281.6	79.2	(69.1-90.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	84	108.4	77.5	(61.8-95.9)	Male	113	99.9	113.1	(93.2-135.9)
Female	74	98.2	75.4	(59.2-94.6)	Female	128	86.3	148.3	(123.7-176.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	20	17.0	117.5	(71.7-181.5)	Male	264	289.1	91.3	(80.6-103.0)
Female	1951	2117.3	92.1	(88.1-96.3)	Female	258	262.3	98.4	(86.7-111.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	95	75.4	126.0	(101.9-154.0)	Male	271	237.4	114.2	(101.0-128.6)
<u>Colon / Rectum</u>					Female	107	116.2	92.1	(75.4-111.2)
Male	555	513.5	108.1	(99.3-117.5)	<u>Ovary</u>				
Female	545	534.1	102.0	(93.7-111.0)	Female	181	187.1	96.7	(83.1-111.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	122	122.7	99.4	(82.6-118.7)	Male	174	178.5	97.5	(83.5-113.1)
Female	26	36.1	72.1	(47.1-105.6)	Female	187	191.6	97.6	(84.1-112.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	49	54.9	89.2	(66.0-118.0)	Male	1737	1459.5	119.0	(113.5-124.7)
Female	39	52.1	74.9	(53.3-102.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	170	114.0	149.2	(127.6-173.4)
Male	255	288.7	88.3	(77.8-99.8)	Female	123	75.6	162.7	(135.2-194.1)
Female	167	170.1	98.2	(83.9-114.3)	<u>Testis</u>				
<u>Larynx</u>					Male	95	110.4	86.0	(69.6-105.1)
Male	90	71.5	125.8	(101.2-154.7)	<u>Thyroid</u>				
Female	21	23.0	91.1	(56.4-139.3)	Male	140	146.8	95.4	(80.2-112.6)
<u>Leukemia</u>					Female	436	462.7	94.2	(85.6-103.5)
Male	185	212.0	87.3	(75.1-100.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	151	162.4	93.0	(78.7-109.0)	Female	447	478.2	93.5	(85.0-102.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	254	173.3	146.5	(129.1-165.7)	Male	6566	6345.0	103.5	(101.0-106.0)
Female	99	63.1	157.0	(127.6-191.1)	Female	6881	7198.6	95.6	(93.3-97.9)
<u>Lung and Bronchus</u>									
Male	872	839.4	103.9	(97.1-111.0)					
Female	880	968.2	90.9	(85.0-97.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	28.4	144.6	(103.7-196.1)	Male	32	17.2	185.8	(127.1-262.3)
Female	10	10.4	95.9	(45.9-176.3)	Female	16	13.0	123.3	(70.4-200.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.7	nc	(nc-nc)	Male	8	5.6	142.4	(61.3-280.7)
Female	3	4.1	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	12	15.3	78.6	(40.6-137.4)
Female	87	105.8	82.3	(65.9-101.5)	Female	10	13.7	73.1	(35.0-134.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.1	nc	(nc-nc)	Male	17	12.1	141.0	(82.1-225.7)
<u>Colon / Rectum</u>					Female	7	6.0	117.2	(47.0-241.6)
Male	28	28.1	99.5	(66.1-143.8)	<u>Ovary</u>				
Female	29	28.9	100.2	(67.1-144.0)	Female	12	9.2	130.4	(67.3-227.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.8	117.4	(50.6-231.4)	Male	8	10.2	78.5	(33.8-154.7)
Female	2	2.0	nc	(nc-nc)	Female	12	11.0	109.5	(56.5-191.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.6	nc	(nc-nc)	Male	82	78.9	103.9	(82.7-129.0)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	6.4	139.7	(63.8-265.3)
Male	13	14.8	87.6	(46.6-149.8)	Female	6	4.1	146.8	(53.6-319.4)
Female	10	8.7	115.4	(55.2-212.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.6	nc	(nc-nc)
Male	11	4.0	276.7	(138.0-495.2)	<u>Thyroid</u>				
Female	4	1.2	nc	(nc-nc)	Male	5	6.0	83.6	(26.9-195.1)
<u>Leukemia</u>					Female	23	16.9	136.1	(86.2-204.2)
Male	7	10.7	65.3	(26.2-134.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	7.9	76.4	(27.9-166.3)	Female	22	24.4	90.1	(56.4-136.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	9.3	85.8	(36.9-169.0)	Male	378	340.7	111.0	(100.0-122.7)
Female	3	3.4	nc	(nc-nc)	Female	345	363.8	94.8	(85.1-105.4)
<u>Lung and Bronchus</u>									
Male	54	49.1	110.0	(82.6-143.5)					
Female	56	53.8	104.2	(78.7-135.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.9	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	5	3.0	167.5	(54.0-391.0)
Female	22	21.2	103.6	(64.9-156.9)	Female	1	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	3	5.7	nc	(nc-nc)	<u>Ovary</u>				
Female	5	4.3	117.1	(37.7-273.2)	Female	0	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	16	17.5	91.7	(52.4-148.9)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.7	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.5	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	1.2	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.0	nc	(nc-nc)	Male	60	68.6	87.5	(66.8-112.7)
Female	0	0.5	nc	(nc-nc)	Female	64	63.8	100.3	(77.2-128.1)
<u>Lung and Bronchus</u>									
Male	6	8.8	68.1	(24.9-148.3)					
Female	8	7.7	103.7	(44.7-204.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.8	82.0	(35.3-161.5)	Male	10	6.6	150.9	(72.3-277.6)
Female	2	3.3	nc	(nc-nc)	Female	11	4.7	233.9	(116.6-418.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
Female	34	39.7	85.7	(59.3-119.7)	Female	5	4.6	109.8	(35.4-256.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	0	5.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.1	nc	(nc-nc)
Male	3	10.7	nc	(nc-nc)	<u>Ovary</u>				
Female	8	9.2	86.5	(37.3-170.5)	Female	1	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.6	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	36	32.4	111.0	(77.8-153.7)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.4	nc	(nc-nc)
Male	4	6.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	10	7.3	137.3	(65.7-252.5)
Male	5	3.9	127.1	(41.0-296.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.6	nc	(nc-nc)	Female	7	9.2	76.0	(30.4-156.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.8	nc	(nc-nc)	Male	99	131.8	75.1	(61.0-91.4)
Female	0	1.1	nc	(nc-nc)	Female	120	128.4	93.5	(77.5-111.8)
<u>Lung and Bronchus</u>									
Male	8	17.9	44.8	(19.3-88.2)					
Female	13	17.7	73.2	(39.0-125.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.6	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	6	2.6	231.9	(84.7-504.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	26	20.7	125.8	(82.1-184.3)	Female	0	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	5	5.9	85.0	(27.4-198.3)	<u>Ovary</u>				
Female	8	5.4	149.1	(64.2-293.7)	Female	1	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	16	16.4	97.3	(55.6-158.0)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.9	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.5	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.0	nc	(nc-nc)	Male	63	69.9	90.1	(69.3-115.3)
Female	1	0.6	nc	(nc-nc)	Female	71	68.7	103.4	(80.7-130.4)
<u>Lung and Bronchus</u>									
Male	5	9.6	52.1	(16.8-121.6)					
Female	6	9.2	65.6	(23.9-142.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	40.5	101.3	(72.7-137.5)	Male	26	25.6	101.5	(66.3-148.8)
Female	17	17.3	98.5	(57.4-157.8)	Female	23	22.5	102.4	(64.9-153.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	7.5	66.5	(21.4-155.2)	Male	7	8.2	85.6	(34.3-176.4)
Female	7	7.2	96.8	(38.8-199.5)	Female	3	7.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.4	nc	(nc-nc)	Male	21	22.7	92.6	(57.3-141.6)
Female	194	175.3	110.6	(95.6-127.4)	Female	20	22.9	87.4	(53.4-135.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.7	105.7	(38.6-230.0)	Male	20	18.4	108.6	(66.3-167.7)
<u>Colon / Rectum</u>					Female	10	9.8	101.6	(48.6-186.8)
Male	46	41.8	109.9	(80.5-146.6)	<u>Ovary</u>				
Female	64	49.2	130.1	(100.2-166.2)	Female	16	15.3	104.3	(59.6-169.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	9.9	90.7	(41.4-172.2)	Male	14	14.7	95.2	(52.0-159.7)
Female	6	3.3	182.3	(66.6-396.8)	Female	19	18.2	104.6	(62.9-163.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	2.9	207.7	(75.8-452.0)	Male	120	114.1	105.2	(87.2-125.8)
Female	4	2.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	9.4	96.1	(43.9-182.5)
Male	25	22.5	111.3	(72.0-164.3)	Female	7	7.0	100.5	(40.2-207.0)
Female	12	14.4	83.6	(43.2-146.1)	<u>Testis</u>				
<u>Larynx</u>					Male	6	5.5	109.8	(40.1-239.1)
Male	4	5.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	2.0	nc	(nc-nc)	Male	10	10.1	99.4	(47.6-182.8)
<u>Leukemia</u>					Female	29	31.2	93.0	(62.2-133.5)
Male	8	16.2	49.5	(21.3-97.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	13.7	124.1	(72.3-198.8)	Female	48	38.7	123.9	(91.4-164.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	16	13.8	116.2	(66.4-188.7)	Male	500	501.4	99.7	(91.2-108.9)
Female	4	5.5	nc	(nc-nc)	Female	651	608.0	107.1	(99.0-115.6)
<u>Lung and Bronchus</u>									
Male	66	69.5	95.0	(73.5-120.9)					
Female	88	86.9	101.3	(81.3-124.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	19.7	81.4	(46.5-132.2)	Male	18	11.6	155.0	(91.8-244.9)
Female	6	7.1	84.3	(30.8-183.4)	Female	8	8.1	98.4	(42.4-193.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.9	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	12	10.1	119.2	(61.5-208.2)
Female	96	67.9	141.3	(114.5-172.6)	Female	17	9.0	189.0	(110.1-302.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.8	nc	(nc-nc)	Male	5	8.1	61.7	(19.9-144.0)
<u>Colon / Rectum</u>					Female	5	3.9	127.0	(40.9-296.4)
Male	10	18.7	53.6	(25.7-98.6)	<u>Ovary</u>				
Female	15	19.1	78.7	(44.0-129.8)	Female	7	5.9	117.9	(47.2-242.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.8	104.6	(33.7-244.1)	Male	4	7.0	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	3	7.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	55	55.6	98.9	(74.5-128.7)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	4.4	nc	(nc-nc)
Male	4	10.0	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
Female	6	5.7	105.4	(38.5-229.5)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.8	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
<u>Leukemia</u>					Female	5	9.3	54.0	(17.4-126.1)
Male	9	7.0	128.7	(58.7-244.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.1	136.5	(54.7-281.3)	Female	16	16.2	98.6	(56.3-160.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	6.3	126.4	(54.4-249.1)	Male	205	232.3	88.3	(76.6-101.2)
Female	0	2.2	nc	(nc-nc)	Female	239	237.3	100.7	(88.3-114.3)
<u>Lung and Bronchus</u>									
Male	31	35.0	88.6	(60.2-125.7)					
Female	26	36.9	70.4	(46.0-103.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	27.6	94.1	(61.5-137.9)	Male	16	17.9	89.3	(51.0-145.1)
Female	11	8.0	136.7	(68.1-244.6)	Female	21	11.8	178.2	(110.2-272.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.5	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
Female	6	4.1	145.5	(53.1-316.7)	Female	3	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	10	16.1	61.9	(29.6-113.9)
Female	87	96.3	90.3	(72.4-111.4)	Female	11	11.4	96.2	(48.0-172.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.2	nc	(nc-nc)	Male	13	13.5	96.1	(51.1-164.4)
<u>Colon / Rectum</u>					Female	4	5.2	nc	(nc-nc)
Male	35	29.6	118.4	(82.5-164.7)	<u>Ovary</u>				
Female	23	23.1	99.4	(63.0-149.1)	Female	9	8.2	109.5	(49.9-207.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	7.0	85.5	(31.2-186.1)	Male	12	10.3	116.3	(60.0-203.1)
Female	0	1.6	nc	(nc-nc)	Female	9	8.3	107.8	(49.2-204.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.3	nc	(nc-nc)	Male	74	84.7	87.4	(68.6-109.7)
Female	0	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.5	76.6	(24.7-178.7)
Male	13	16.4	79.5	(42.3-136.0)	Female	2	3.3	nc	(nc-nc)
Female	8	7.5	106.2	(45.7-209.2)	<u>Testis</u>				
<u>Larynx</u>					Male	2	4.2	nc	(nc-nc)
Male	2	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	9	7.6	118.8	(54.2-225.5)
<u>Leukemia</u>					Female	28	18.3	153.1	(101.7-221.3)
Male	8	11.6	69.2	(29.8-136.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	6.7	nc	(nc-nc)	Female	26	22.2	117.1	(76.4-171.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	9.9	141.1	(77.1-236.8)	Male	333	357.7	93.1	(83.4-103.6)
Female	1	2.8	nc	(nc-nc)	Female	319	316.1	100.9	(90.1-112.6)
<u>Lung and Bronchus</u>									
Male	55	47.6	115.6	(87.1-150.5)					
Female	43	42.9	100.2	(72.5-135.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.0	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	15	18.2	82.6	(46.2-136.2)	Female	5	2.0	247.1	(79.6-576.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	1	4.5	nc	(nc-nc)	<u>Ovary</u>				
Female	2	3.9	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.2	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.3	nc	(nc-nc)	Male	8	15.0	53.4	(23.0-105.2)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.0	nc	(nc-nc)
Male	6	2.7	219.2	(80.0-477.1)	Female	1	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.2	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.1	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.7	nc	(nc-nc)	Male	51	57.1	89.3	(66.5-117.4)
Female	0	0.5	nc	(nc-nc)	Female	41	57.5	71.3	(51.1-96.7)
<u>Lung and Bronchus</u>									
Male	6	7.5	79.8	(29.1-173.7)					
Female	5	7.9	63.0	(20.3-147.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	85	86.8	98.0	(78.3-121.2)	Male	27	57.0	47.3	(31.2-68.9)
Female	32	33.0	96.8	(66.2-136.7)	Female	30	48.0	62.5	(42.1-89.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	18.0	89.1	(50.9-144.8)	Male	14	18.2	77.0	(42.1-129.2)
Female	21	15.9	131.8	(81.6-201.5)	Female	17	15.4	110.5	(64.4-177.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	3.1	nc	(nc-nc)	Male	45	50.9	88.4	(64.5-118.3)
Female	325	379.4	85.7	(76.6-95.5)	Female	40	45.9	87.1	(62.2-118.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	28	12.9	216.5	(143.8-312.8)	Male	41	43.2	94.9	(68.1-128.7)
<u>Colon / Rectum</u>					Female	25	20.4	122.4	(79.2-180.7)
Male	111	93.4	118.8	(97.7-143.1)	<u>Ovary</u>				
Female	98	95.6	102.5	(83.2-125.0)	Female	40	32.8	122.1	(87.2-166.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	25	22.3	112.1	(72.5-165.5)	Male	38	32.6	116.5	(82.5-159.9)
Female	8	6.5	123.9	(53.3-244.1)	Female	52	34.4	151.3	(113.0-198.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	7.2	111.7	(48.1-220.1)	Male	265	265.8	99.7	(88.1-112.5)
Female	6	6.6	91.3	(33.3-198.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	26	20.7	125.8	(82.2-184.4)
Male	72	52.1	138.1	(108.1-173.9)	Female	13	13.4	96.8	(51.5-165.5)
Female	30	30.3	99.1	(66.9-141.5)	<u>Testis</u>				
<u>Larynx</u>					Male	13	13.7	94.8	(50.4-162.1)
Male	17	13.0	131.1	(76.3-209.9)	<u>Thyroid</u>				
Female	6	4.2	144.2	(52.7-314.0)	Male	26	24.3	107.1	(69.9-156.9)
<u>Leukemia</u>					Female	86	74.7	115.1	(92.1-142.2)
Male	26	36.9	70.5	(46.1-103.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	18	27.8	64.7	(38.3-102.3)	Female	88	84.6	104.0	(83.4-128.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	46	31.6	145.6	(106.6-194.2)	Male	1185	1132.3	104.7	(98.8-110.8)
Female	15	11.1	135.6	(75.8-223.6)	Female	1291	1267.6	101.8	(96.4-107.6)
<u>Lung and Bronchus</u>									
Male	182	151.0	120.5	(103.7-139.4)					
Female	205	174.1	117.8	(102.2-135.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.8	132.8	(42.8-309.9)	Male	3	2.5	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	12	16.0	74.9	(38.7-130.9)	Female	4	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.9	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	<u>Ovary</u>				
Female	4	4.0	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.0	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	15	13.0	115.5	(64.6-190.5)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.9	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.9	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	51	51.0	100.1	(74.5-131.6)
Female	2	0.5	nc	(nc-nc)	Female	63	53.6	117.6	(90.4-150.5)
<u>Lung and Bronchus</u>									
Male	10	7.0	143.0	(68.5-263.1)					
Female	18	7.6	235.4	(139.4-372.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	55.9	84.1	(61.8-111.8)	Male	51	35.5	143.6	(106.9-188.8)
Female	16	22.4	71.3	(40.7-115.8)	Female	32	31.2	102.7	(70.2-145.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	10.8	74.3	(32.0-146.3)	Male	9	11.4	79.0	(36.1-150.0)
Female	14	10.7	131.4	(71.8-220.6)	Female	7	10.3	67.9	(27.2-139.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.9	nc	(nc-nc)	Male	35	31.5	111.0	(77.3-154.3)
Female	222	242.6	91.5	(79.9-104.4)	Female	36	30.5	118.1	(82.7-163.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	7.9	nc	(nc-nc)	Male	29	25.9	112.0	(75.0-160.9)
<u>Colon / Rectum</u>					Female	7	13.6	51.5	(20.6-106.2)
Male	30	56.9	52.8	(35.6-75.3)	<u>Ovary</u>				
Female	41	62.4	65.7	(47.2-89.2)	Female	31	21.3	145.4	(98.8-206.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	14.1	nc	(nc-nc)	Male	18	20.5	87.6	(51.9-138.5)
Female	3	4.5	nc	(nc-nc)	Female	26	23.5	110.6	(72.2-162.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	4.6	129.6	(47.3-282.0)	Male	155	169.7	91.3	(77.5-106.9)
Female	7	5.0	139.0	(55.7-286.5)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	13.0	76.9	(36.8-141.5)
Male	31	31.7	97.7	(66.4-138.7)	Female	6	8.9	67.7	(24.7-147.3)
Female	16	19.8	81.0	(46.2-131.5)	<u>Testis</u>				
<u>Larynx</u>					Male	12	8.7	137.2	(70.8-239.7)
Male	2	8.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	2.8	nc	(nc-nc)	Male	16	14.3	112.1	(64.0-182.0)
<u>Leukemia</u>					Female	46	46.9	98.2	(71.9-131.0)
Male	33	22.6	145.8	(100.4-204.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	22	18.6	118.6	(74.3-179.5)	Female	46	56.4	81.5	(59.7-108.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	19.2	62.4	(32.2-108.9)	Male	607	711.1	85.4	(78.7-92.4)
Female	3	7.4	nc	(nc-nc)	Female	740	832.1	88.9	(82.6-95.6)
<u>Lung and Bronchus</u>									
Male	47	98.6	47.7	(35.0-63.4)					
Female	74	118.3	62.5	(49.1-78.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	4	10.5	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.6	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	7.6	91.6	(36.7-188.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	3	1.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	0	2.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	24	31.1	77.3	(49.5-115.0)
Female	0	0.3	nc	(nc-nc)	Female	24	34.8	69.0	(44.2-102.7)
<u>Lung and Bronchus</u>									
Male	1	4.4	nc	(nc-nc)					
Female	7	5.1	137.8	(55.2-284.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	33.5	80.7	(53.2-117.4)	Male	19	20.4	93.3	(56.1-145.6)
Female	8	11.3	70.8	(30.5-139.6)	Female	11	15.0	73.2	(36.5-131.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.7	88.5	(28.5-206.4)	Male	6	6.5	92.5	(33.8-201.2)
Female	5	4.9	102.4	(33.0-238.9)	Female	4	5.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	24	17.9	134.0	(85.8-199.3)
Female	131	123.6	105.9	(88.6-125.7)	Female	13	15.1	85.9	(45.7-146.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.9	nc	(nc-nc)	Male	10	13.6	73.4	(35.1-135.0)
<u>Colon / Rectum</u>					Female	5	6.7	74.8	(24.1-174.6)
Male	27	33.1	81.7	(53.8-118.8)	<u>Ovary</u>				
Female	30	31.4	95.6	(64.5-136.5)	Female	9	10.5	85.6	(39.1-162.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	7.7	nc	(nc-nc)	Male	19	11.7	161.8	(97.3-252.6)
Female	1	2.2	nc	(nc-nc)	Female	7	11.7	60.0	(24.0-123.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.1	nc	(nc-nc)	Male	75	83.9	89.4	(70.3-112.0)
Female	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.5	79.9	(29.2-174.0)
Male	16	16.9	94.6	(54.1-153.7)	Female	3	4.4	nc	(nc-nc)
Female	5	10.0	49.9	(16.1-116.6)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.9	nc	(nc-nc)
Male	2	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.4	nc	(nc-nc)	Male	8	7.3	110.3	(47.5-217.4)
<u>Leukemia</u>					Female	31	22.0	141.0	(95.8-200.2)
Male	16	12.8	125.1	(71.5-203.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.8	56.7	(18.3-132.4)	Female	34	27.6	123.1	(85.2-172.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	10.5	76.4	(32.9-150.6)	Male	352	390.9	90.0	(80.9-100.0)
Female	3	3.6	nc	(nc-nc)	Female	395	415.1	95.2	(86.0-105.0)
<u>Lung and Bronchus</u>									
Male	39	56.9	68.6	(48.8-93.8)					
Female	60	61.1	98.3	(75.0-126.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	77.2	67.4	(50.3-88.4)	Male	52	50.3	103.4	(77.2-135.6)
Female	16	29.9	53.6	(30.6-87.0)	Female	52	44.6	116.6	(87.1-153.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	20	17.5	114.5	(69.9-176.8)	Male	15	15.7	95.6	(53.4-157.6)
Female	15	15.9	94.1	(52.6-155.2)	Female	9	13.8	65.1	(29.7-123.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.7	nc	(nc-nc)	Male	47	45.8	102.6	(75.4-136.4)
Female	326	328.6	99.2	(88.7-110.6)	Female	49	41.9	116.9	(86.5-154.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	11.5	52.3	(19.1-113.9)	Male	40	35.7	112.1	(80.1-152.6)
<u>Colon / Rectum</u>					Female	18	18.5	97.3	(57.7-153.8)
Male	70	79.1	88.5	(69.0-111.9)	<u>Ovary</u>				
Female	64	83.7	76.5	(58.9-97.6)	Female	31	29.5	105.2	(71.4-149.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	16	19.3	83.0	(47.4-134.8)	Male	28	28.1	99.7	(66.2-144.1)
Female	10	5.9	170.6	(81.7-313.8)	Female	26	30.9	84.2	(55.0-123.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	11	9.8	112.7	(56.2-201.6)	Male	255	227.4	112.1	(98.8-126.8)
Female	4	9.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	17.9	66.9	(34.5-116.9)
Male	33	43.8	75.3	(51.8-105.7)	Female	10	12.0	83.5	(40.0-153.6)
Female	17	26.9	63.2	(36.8-101.2)	<u>Testis</u>				
<u>Larynx</u>					Male	24	19.5	122.9	(78.7-182.9)
Male	5	11.1	44.9	(14.5-104.7)	<u>Thyroid</u>				
Female	0	3.7	nc	(nc-nc)	Male	25	22.5	111.0	(71.8-163.9)
<u>Leukemia</u>					Female	84	72.4	116.0	(92.5-143.6)
Male	32	34.0	94.1	(64.4-132.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	26.0	61.5	(35.1-99.8)	Female	67	76.0	88.1	(68.3-111.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	19	26.6	71.3	(42.9-111.4)	Male	928	1000.3	92.8	(86.9-98.9)
Female	10	10.1	98.9	(47.4-182.0)	Female	1020	1139.5	89.5	(84.1-95.2)
<u>Lung and Bronchus</u>									
Male	99	134.8	73.4	(59.7-89.4)					
Female	112	157.4	71.2	(58.6-85.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	27.1	70.2	(42.2-109.6)	Male	21	16.9	124.1	(76.8-189.7)
Female	5	9.5	52.5	(16.9-122.6)	Female	15	13.1	114.5	(64.1-188.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.8	145.4	(58.2-299.5)	Male	13	5.4	240.2	(127.8-410.8)
Female	6	4.2	142.4	(52.0-309.9)	Female	5	4.4	114.4	(36.9-266.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	13	15.0	86.8	(46.2-148.4)
Female	113	104.6	108.0	(89.0-129.9)	Female	15	12.9	116.2	(65.0-191.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.5	143.2	(46.2-334.2)	Male	11	12.0	92.0	(45.9-164.6)
<u>Colon / Rectum</u>					Female	5	5.7	88.0	(28.4-205.4)
Male	34	27.4	123.9	(85.8-173.2)	<u>Ovary</u>				
Female	30	27.3	109.8	(74.1-156.8)	Female	9	9.0	100.2	(45.7-190.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	6.5	91.6	(33.5-199.4)	Male	11	9.8	112.0	(55.9-200.5)
Female	0	1.9	nc	(nc-nc)	Female	8	10.0	80.2	(34.5-158.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.8	nc	(nc-nc)	Male	87	76.0	114.5	(91.7-141.3)
Female	1	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	6.2	128.7	(55.4-253.6)
Male	9	14.8	60.9	(27.8-115.7)	Female	3	3.8	nc	(nc-nc)
Female	7	8.4	83.6	(33.5-172.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.3	nc	(nc-nc)
Male	3	3.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	1.1	nc	(nc-nc)	Male	11	6.4	170.8	(85.1-305.6)
<u>Leukemia</u>					Female	31	19.4	159.5	(108.4-226.5)
Male	16	10.6	151.1	(86.3-245.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	7.7	78.0	(28.5-169.7)	Female	25	23.2	107.9	(69.8-159.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	9.0	nc	(nc-nc)	Male	360	331.6	108.6	(97.6-120.4)
Female	0	3.1	nc	(nc-nc)	Female	380	352.3	107.9	(97.3-119.3)
<u>Lung and Bronchus</u>									
Male	46	46.9	98.2	(71.9-131.0)					
Female	55	49.4	111.4	(83.9-145.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;